Dr. Brinda Emu Provides Insight into HIV Monoclonal Antibody Ibalizumab
OCT 19, 2017 | CONTAGION® EDITORIAL STAFF
Brinda Emu, MD, of the Infectious Diseases department at Yale University, offers insight into monoclonal antibody ibalizumab. Dr. Emu explains that the antiretroviral binds CD4—the primary receptor for HIV—and inhibits the viral entry process. Ibalizumab is active against all major HIV clades.
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512